You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | n/a |
Div Cover | n/a | n/a |
Op Mrgn | 6.6% | n/a |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | 69.5 | n/a |
PEG | -1.0 | n/a |
Price / Revenue | 3.8 | n/a |
Price / Book value | 3.1 |
Latest | Forecast | |
---|---|---|
Revenue | -24.8% | 11.5% |
PBT | 0.0% | n/a |
EPS | -66.7% | 44.1% |
DPS | n/a | 0.0% |
Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2020-12-31 | 227.98 | -189.73 | $-0.18 | -34.9 | 0.0 | n/a | n/a | 0.0% |
2021-12-31 | 356.13 | -215.74 | $0.00 | -2,840.3 | 0.0 | n/a | n/a | 0.0% |
2022-12-31 | 426.41 | -410.42 | $-0.43 | -7.4 | 0.0 | n/a | n/a | 0.0% |
2023-12-31 | 838.00 | 58.31 | $0.12 | 30.0 | 0.0 | n/a | n/a | 0.0% |
2024-12-31 | 630.20 | -1.11 | $0.04 | 73.5 | -1.1 | -67% | n/a | 0.0% |
Hutchmed enrols patients for phase two savolitinib trial Sharecast News | 22 Apr |
---|---|
Hutchmed renal cell carcinoma trial meets primary endpoint Sharecast News | 19 Mar |
Hutchmed announces progress, hits milestone with lung cancer treatment Sharecast News | 02 Jan |
AGM held on May 13, 2025 – Poll Results | 13-May-25 11:45 |
---|---|
2024 Annual Report and Notice of AGM | 07-Apr-25 09:30 |
Extraordinary General Meeting – Poll Results | 31-Mar-25 22:52 |
Retirement of Independent Non-executive Directors | 20-Mar-25 09:31 |
2024 Final Results and Business Updates | 19-Mar-25 22:56 |